logo

For the Inventor, By the Inventor

Puschino, Russia

Andrei Borisovich Ulitin

This inventor holds 7 USPTO granted patents and 1 published patent application. Top assignees: Joint Stock Company "Biocad", Other. Active years: 2021-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Andrei Borisovich Ulitin. Retrieved from https://idiyas.com/inventor/andrei-borisovich-ulitin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 7 

% Patents Active = 100.0

Average Co-Inventor Count = 9.7

ph-index = 2

Forward Citations = 5(Granted Patents)


Location History:

  • Puschino Moskovskaya obl., RU (2022)
  • Puschino, RU (2021 - 2024)

Company Filing History:

goldMedal2 out of 11 
 
Joint Stock Company "Biocad"
 patents
silverMedal3 out of 834,453 
Other
 patents
where one patent can have more than one assignee

Years Active: 2021-2026

Loading Chart...
7 patents (USPTO):Explore Patents
1. 12540169 - ALTERNATIVE INTRACELLULAR SIGNALLING DOMAIN OF A CHIMERIC ANTIGEN RECEPTOR (2026-02-03),
2. 12410257 - Monoclonal antibody that binds specifically to GITR (2025-09-09),
3. 11993647 - Antibody or an antigen-binding fragment thereof capable of binding to a human receptor of interleukin-6 (2024-05-28),
4. 11840567 - Bispecific antibodies with specific binding to CD47 and PD-L1 (2023-12-12),
5. 11453717 - Trispecific antibodies against IL-17A, IL-17F and other pro-inflammatory molecule (2022-09-27),
6. 11236167 - Monoclonal antibody to PD-L1 (2022-02-01),
7. 11136408 - Anti-PD-1 antibodies, method for producing same and method for using same (2021-10-05),

Title: Andrei Borisovich Ulitin: Innovator in Biotechnology

Introduction

Andrei Borisovich Ulitin is a prominent inventor based in Puschino, Russia. He has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 7 patents to his name, Ulitin's work is paving the way for advancements in medical treatments.

Latest Patents

Ulitin's latest patents include a monoclonal antibody that binds specifically to GITR. This invention relates to biotechnology and focuses on antibodies or antigen-binding fragments, as well as their applications. The invention also encompasses a nucleic acid encoding the antibody, an expression vector, and methods for preparing the antibody, which can be used in treating diseases associated with GITR. Another notable patent involves an antibody or antigen-binding fragment capable of binding to a human receptor of interleukin-6. This invention addresses the need for alternative antibodies that can specifically bind to this receptor, offering potential therapeutic applications for diseases mediated by interleukin-6.

Career Highlights

Throughout his career, Ulitin has demonstrated a commitment to innovation in the medical field. His research has led to the development of novel therapeutic agents that have the potential to improve patient outcomes. His expertise in biotechnology has positioned him as a key figure in the advancement of antibody-based treatments.

Collaborations

Ulitin has collaborated with notable colleagues, including Valery Vladimirovich Solovyev and Dmitry Valentinovich Morozov. These partnerships have fostered a collaborative environment that enhances the research and development of innovative solutions in biotechnology.

Conclusion

Andrei Borisovich Ulitin's contributions to biotechnology through his patents and collaborations highlight his role as an influential inventor. His work continues to impact the medical field, offering promising avenues for treatment and diagnosis.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…